NexusPharma

NexusPharma is dedicated to discovering new anti-cancer therapies. New candidate drugs will be tested in patient-derived xenograft (PDX) models or patient-derived tumor cell lines, which are sourced from PDX models—models that the company is developing to reflect human disease in the most predictable manner. NexusPharma combines the design and application of chemical and bioinformatics algorithms with its cell-based assay systems, forming a multidisciplinary approach characterized by state-of-the-art medicinal chemistry, innovative biology, and drug development. This process underpins the company’s value proposition of creating novel small-molecule compounds that will become future drugs, improving the quality of human life.